Regulatory coverage on Peptide News Digest tracks how the FDA, MHRA, EMA, and state agencies handle peptides — what they let through, what they pull, what they redefine.
The compounding fight has dominated 2025 and 2026. GLP-1s came off the FDA shortage list in early 2025; the agency moved compounded semaglutide and tirzepatide toward Category 2 on the 503A bulks list; and a wave of state legislation tried to either preserve or shut off telehealth access. The PCAC has spent meetings on BPC-157, GHK-Cu, and other research peptides that have built consumer demand without clinical infrastructure behind them.
Stories here name the agency, the substance, and the action. Browse the latest below, or jump to specific tags like #fda, #compounding, #peptide-policy, or #503a.
A JAMA Medical News report published October 9, 2026 found dozens of websites, promoted by TikTok and Instagram influencers, selling Eli Lilly's investigational triple agonist retatrutide and Novo Nordisk's GLP-1 and amylin drug zenagamtide, often labeled "for research purposes only" while giving dosing instructions. Neither drug is approved anywhere. Australia's drug regulator found a product labeled retatrutide that contained a high dose of semaglutide instead, and University of Queensland tests of three 10 mg vials found doses from about half to about twice the label; the FDA has sent 21 warning letters to retatrutide sellers since December 2024, according to the report.
BioMarin said on October 9, 2026 that it has submitted a supplemental application to the FDA for Voxzogo (vosoritide), a C-type natriuretic peptide analog approved for achondroplasia, in hypochondroplasia, a milder genetic form of short stature, with filings in Europe and other regions on track and a possible 2027 launch if approved. Phase 3 results showing faster growth in children with hypochondroplasia are among 13 studies the company is presenting at the ASBMR meeting in Boston, though the release gives no growth figures. A separate application with long-term achondroplasia data has an FDA decision date of February 28, 2027.
The World Health Organization published its first guidelines on managing obesity in children and in adolescents on October 7, 2026. For children up to age 9, it makes a strong recommendation against weight-loss medicines, based on low-quality evidence. For ages 10 to 19, it conditionally suggests medicines only for teens who have obesity-related complications, such as type 2 diabetes or uncontrolled high blood pressure, and whose weight has not improved after a supervised diet, exercise, and behavior program lasting at least six months; treatment should be given by a specialist team with long-term follow-up. WHO's evidence review found mostly short trials and noted that teens taking GLP-1 drugs or orlistat stopped more often because of side effects.
Novo Nordisk said on Friday, October 2, 2026 that the FDA's review of its biologics license application for denecimig, a bispecific antibody that mimics activated clotting factor VIII in hemophilia A, is still ongoing with no new action date because of remediation work at a manufacturing facility. Novo filed in September 2025 and had expected a decision in the third quarter of 2026; the FDA has not identified deficiencies in the clinical efficacy or safety data, and Novo now aims to launch in the U.S. in the first half of 2027. The company said the delay does not change its 2026 financial outlook.
STAT reported on Monday, October 5, 2026 from PepMed 2026, a conference for regenerative health businesses held by the American Academy of Peptide Medicine, that stem cell entrepreneurs see the FDA's recent openness to compounded peptides as a model for bringing unapproved stem cell therapies out of the gray market. Entrepreneur Chuck Meeker predicted a series of FDA roundtables on stem cells before the end of the year; the FDA declined to say whether any were planned. Commercially sold, unapproved stem cell therapies have remained out of favor with the agency.
As of Thursday, October 1, 2026, Rhode Island Medicaid no longer covers GLP-1 drugs such as Wegovy, Zepbound, and Saxenda when they are prescribed for weight loss, Rhode Island Current reported; the drugs remain covered for other conditions such as type 2 diabetes. The program paid for 24,971 GLP-1 prescriptions for obesity in fiscal year 2025, and state officials estimated the change would save $6.3 million in state general revenue and $20.3 million in combined state and federal funds. California, New Hampshire, Pennsylvania, South Carolina, Utah, and Massachusetts also ended or did not renew Medicaid obesity coverage this year.
The Saudi Food and Drug Authority said, as reported on Wednesday, September 30, 2026, that it had found unregistered peptide products of unknown origin being marketed on websites and social media without required licenses, some with claims that they could rapidly cause weight loss, build muscle, or slow aging. The agency said it has started legal action against the store owners and is preparing cases for referral to the Public Prosecution; violations carry fines of up to SR5 million (about $1.4 million), up to five years in prison, or both. The SFDA did not name specific products and urged consumers to buy peptides only from reliable sources after consulting a physician.
Oncopeptides announced on Thursday, September 17, 2026 that the European Medicines Agency's CHMP adopted a positive opinion to extend the indication of Pepaxti (melflufen), given with dexamethasone, to adults with multiple myeloma who have had at least two prior lines of therapy and whose disease is refractory to lenalidomide and to the last line of therapy. Pepaxti's current EU label covers fourth-line and later patients whose disease is triple-class refractory, so the change would drop that requirement; the opinion rests on the Phase 3 OCEAN trial, and the European Commission is expected to decide within 30 to 60 days. Oncopeptides CEO Sofia Heigis said the broader label 'effectively doubles' the company's addressable patient population. The FDA withdrew the U.S. approval of the same drug, sold there as Pepaxto, on February 23, 2024, after concluding that the OCEAN confirmatory trial did not confirm its clinical benefit.
Rhythm Pharmaceuticals announced on Tuesday, September 22, 2026 that Health Canada approved IMCIVREE (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for weight management in adults and children 4 years and older with acquired hypothalamic obesity, a rare condition that develops after injury to the hypothalamus. Rhythm called it the first targeted therapy approved in Canada for the condition. The approval rests on the Phase 3 TRANSCEND trial in 142 patients, which met its primary endpoint; Rhythm's Canadian announcement gives the placebo-adjusted reduction in body mass index as 18.8%, while its March 19, 2026 U.S. approval announcement reported 18.4% at 52 weeks. IMCIVREE was first approved in Canada in 2023 for obesity due to Bardet-Biedl syndrome or POMC, PCSK1, or LEPR deficiency, and the acquired hypothalamic obesity indication is already authorized in the U.S., the European Union, and the UK.
Eli Lilly announced on Thursday, September 24, 2026 that the FDA approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin used with diet and exercise to control blood sugar in adults with type 2 diabetes; it is not for type 1 diabetes because of an increased risk of severe hypoglycemia. Approval rests on four Phase 3 QWINT trials in more than 3,400 adults, in which efsitora met non-inferiority for A1C reduction against daily insulin glargine (QWINT-1, n=795; QWINT-4, n=730) and insulin degludec (QWINT-2, n=928; QWINT-3, n=986). Onswik will come in U-500 and U-1,000 prefilled pens delivering up to 400 and 800 units per injection, and Lilly expects U.S. availability in the coming months. It is already approved in the European Union, Mexico, and Japan.
Lantheus Holdings announced on Tuesday, September 22, 2026 that the FDA granted final approval to BRAVNETSA (lutetium Lu 177 dotatate) through the Abbreviated New Drug Application pathway for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lantheus says BRAVNETSA is the only radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to Lutathera, which contains the same active ingredient. The company did not give a launch date. Eight days earlier, on September 14, Curium announced FDA approval of BEXLUTRY, another lutetium Lu 177 dotatate for the same indication, approved as a 505(b)(2) NDA and available immediately.
The FDA issued a warning letter dated September 18, 2026 to Houston-based Empower Pharmacy after a November 3-14, 2025 inspection, saying its compounded semaglutide and tirzepatide products appear to be 'essentially copies' of FDA-approved drugs and did not meet the conditions of section 503A. The agency said prescriber determinations of a 'significant difference' appeared to be repeated verbatim across many records, suggesting they may be pre-generated, and called the differences between Empower's products and the approved drugs 'pretextual.' The letter also cites insanitary conditions, including inadequate smoke studies of airflow in the ISO 5 area and media fills not run under the most challenging conditions. Empower has 15 working days to respond; BioSpace reported the letter on September 24.
Johnson & Johnson announced on Monday, September 21, 2026 that the European Commission granted marketing authorization for ICOTYDE (icotrokinra) for adults and adolescents aged 12 and older weighing at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. J&J calls icotrokinra the first targeted oral peptide that precisely blocks the IL-23 receptor; it was jointly discovered and is being developed under J&J's license and collaboration agreement with Protagonist Therapeutics. The approval rests on the ICONIC program of four Phase 3 studies in about 2,500 patients (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and 2). In the head-to-head studies, about 70% of patients on icotrokinra reached clear or almost clear skin (IGA 0/1) and 55% reached PASI 90 at week 16. Patients take one pill once daily with water on waking, at least 30 minutes before eating.
NewAmsterdam Pharma and Menarini Group announced on Monday, September 21, 2026 that the European Commission approved Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for adults with primary hypercholesterolemia, including heterozygous familial and non-familial forms, or mixed dyslipidemia. The companies called it the first regulatory approval of obicetrapib, an oral, low-dose CETP inhibitor, anywhere in the world. The approval cites the Phase 3 BROADWAY, BROOKLYN, and TANDEM trials, which showed LDL-C reductions of up to 40% with obicetrapib alone and about 50% with the ezetimibe combination versus placebo, with tolerability comparable to placebo. Menarini holds exclusive European commercialization rights and pays NewAmsterdam tiered double-digit royalties, with up to €833 million more in milestones.
Insmed announced on Monday, September 21, 2026 that the FDA granted Priority Review to its supplemental New Drug Application for ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial regimen, with a PDUFA target action date of January 28, 2027. The filing rests on the Phase 3b ENCORE study, which enrolled 425 patients, 82.4% of them with a first MAC infection, and met its primary endpoint and its multiplicity-controlled secondary culture-conversion endpoints. ARIKAYCE's PULMOVANCE liposomal technology delivers amikacin to lung macrophages while limiting systemic exposure. The drug received FDA accelerated approval in 2018 for refractory MAC lung disease and was the first product approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.
PureTech Health announced on Monday, September 21, 2026 a successful end-of-Phase 1 meeting with the FDA and Fast Track designation for LYT-200 in combination with a hypomethylating agent (HMA) for relapsed/refractory high-risk myelodysplastic syndromes (HR-MDS). LYT-200 is a fully human monoclonal antibody against galectin-9, developed by PureTech's founded entity Gallop Oncology. In the Phase 1b study, 11 efficacy-evaluable patients who received 12 mg/kg LYT-200 with an HMA had an overall response rate of 45.5% and a complete response rate of 27.3%, with no dose-limiting toxicities. The planned Phase 2 STRIDE-MDS trial will randomize about 125 patients 2:2:1 to 12 mg/kg or 7.5 mg/kg LYT-200 with an HMA, or placebo with an HMA; LYT-200 also holds Fast Track designation in acute myeloid leukemia.
Amneal Pharmaceuticals announced on Friday, September 18, 2026 that the FDA approved its lanreotide injection, 120 mg/0.5 mL, in a sterile single-dose prefilled syringe referencing Somatuline Depot, and that it would launch immediately. The product is indicated for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. The FDA gave it Competitive Generic Therapy designation. Somatuline Depot had U.S. sales of $983 million for the 12 months ended July 2026, according to IQVIA data cited by Amneal.
Novo Nordisk announced on Thursday, September 17, 2026 that the EMA's CHMP recommended marketing authorization for FREHEMGO (denecimig) to treat hemophilia A, with or without inhibitors, in adults and children. Denecimig is a factor VIIIa-mimetic bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of activated factor VIII. Novo says it is the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks, and once-weekly prophylaxis in a single-use pre-filled pen. The application was based on the FRONTIER2, FRONTIER3, and FRONTIER4 trials, and FRONTIER5 showed no new safety signals in patients switching from emicizumab. Pending a European Commission decision, Novo expects launches in the first European countries in Q4 2026 and across the EU starting early 2027.